TranS1 Inc received CE Mark approval to market its VEO lateral access fusion system for interbody fusions in the European Union, according to a release.
Designed for direct visualization of the psoas muscles and adjacent nerves prior to muscle dissection, the VEO minimally invasive lateral system features a two-stage retraction method that focuses on nerve visualization and controlled reaction, the release noted. In addition to PEEK lateral interbody implants and ergonomic instruments, the device features radiopaque markers located within the implants to allow proper placement.
“We are very pleased to receive the CE mark for the VEO lateral system. This approval represents a significant milestone for TranS1 and will contribute to our efforts to become a leader in minimally invasive spine surgery,” Ken Reali, president and CEO of TranS1, stated in the release. “We are excited to begin executing on our commercialization strategy in Europe as we enter the third quarter.”